Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancies
Latest Information Update: 23 Jan 2024
At a glance
- Drugs TQB-2858 (Primary)
- Indications Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 17 Jan 2024 Status changed from not yet recruiting to discontinued.
- 15 Dec 2021 New trial record